MA27028A1 - Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes - Google Patents

Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Info

Publication number
MA27028A1
MA27028A1 MA27409A MA27409A MA27028A1 MA 27028 A1 MA27028 A1 MA 27028A1 MA 27409 A MA27409 A MA 27409A MA 27409 A MA27409 A MA 27409A MA 27028 A1 MA27028 A1 MA 27028A1
Authority
MA
Morocco
Prior art keywords
adenosine
treatment
combined
receptor agonist
air conditions
Prior art date
Application number
MA27409A
Other languages
English (en)
Inventor
Michael Yeadon
Roisin A Armstrong
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275A external-priority patent/GB0129275D0/en
Priority claimed from GB0210238A external-priority patent/GB0210238D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of MA27028A1 publication Critical patent/MA27028A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA27409A 2001-05-25 2003-11-20 Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes MA27028A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29384201P 2001-05-25 2001-05-25
GB0129275A GB0129275D0 (en) 2001-12-06 2001-12-06 Pharmaceutical combination
GB0210238A GB0210238D0 (en) 2002-05-03 2002-05-03 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
MA27028A1 true MA27028A1 (fr) 2004-12-20

Family

ID=27256345

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27409A MA27028A1 (fr) 2001-05-25 2003-11-20 Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes

Country Status (22)

Country Link
US (1) US20040171576A1 (fr)
EP (1) EP1395287A1 (fr)
KR (1) KR20030097901A (fr)
CN (1) CN1535161A (fr)
AP (1) AP2003002911A0 (fr)
BG (1) BG108383A (fr)
BR (1) BR0209986A (fr)
CA (1) CA2448086A1 (fr)
CO (1) CO5540324A2 (fr)
CZ (1) CZ20033126A3 (fr)
EE (1) EE200300586A (fr)
HU (1) HUP0400029A2 (fr)
IL (1) IL158774A0 (fr)
MA (1) MA27028A1 (fr)
MX (1) MXPA03010787A (fr)
NO (1) NO20035202D0 (fr)
OA (1) OA12609A (fr)
PA (1) PA8546101A1 (fr)
PL (1) PL366899A1 (fr)
SK (1) SK14302003A3 (fr)
SV (1) SV2003001055A (fr)
WO (1) WO2002096462A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214665B2 (en) 2001-10-01 2007-05-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
EP1778712B1 (fr) 2004-08-02 2013-01-30 University Of Virginia Patent Foundation Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a2a
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
CA2625664C (fr) 2005-10-21 2016-01-05 Novartis Ag Molecules organiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2664378A1 (fr) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines utilisees comme inhibiteurs des lipides kinases pl3k
CA2667962A1 (fr) 2006-10-30 2008-05-08 Novartis Ag Composes heterocycliques en tant qu'agents anti-inflammatoires
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
CA2770873A1 (fr) 2009-08-12 2011-02-17 Novartis Ag Composes hydrazone heterocycliques et leurs utilisations pour traiter le cancer et l'inflammation
IN2012DN01961A (fr) 2009-08-17 2015-08-21 Intellikine Llc
EP2467383A1 (fr) 2009-08-20 2012-06-27 Novartis AG Composés d'oximes hétérocycliques
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (fr) 2011-02-10 2013-12-18 Novartis AG Composés de [1, 2, 4]triazolo [4, 3 -b]pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
SG192795A1 (en) 2011-02-25 2013-09-30 Irm Llc Compounds and compositions as trk inhibitors
ES2691650T3 (es) 2011-09-15 2018-11-28 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2014151147A1 (fr) 2013-03-15 2014-09-25 Intellikine, Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
CN107207510B (zh) 2014-07-31 2019-11-29 诺华股份有限公司 联合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ATE331726T1 (de) * 1998-10-16 2006-07-15 Pfizer Adenine-derivate
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives

Also Published As

Publication number Publication date
CO5540324A2 (es) 2005-07-29
AP2003002911A0 (en) 2003-12-31
OA12609A (en) 2006-06-09
WO2002096462A1 (fr) 2002-12-05
NO20035202D0 (no) 2003-11-24
BG108383A (bg) 2004-08-31
CA2448086A1 (fr) 2002-12-05
CZ20033126A3 (cs) 2004-09-15
KR20030097901A (ko) 2003-12-31
IL158774A0 (en) 2004-05-12
US20040171576A1 (en) 2004-09-02
CN1535161A (zh) 2004-10-06
SK14302003A3 (sk) 2004-08-03
PL366899A1 (en) 2005-02-07
HUP0400029A2 (hu) 2004-04-28
EE200300586A (et) 2004-04-15
SV2003001055A (es) 2003-11-14
BR0209986A (pt) 2004-04-06
EP1395287A1 (fr) 2004-03-10
PA8546101A1 (es) 2003-12-10
MXPA03010787A (es) 2004-03-02

Similar Documents

Publication Publication Date Title
MA27028A1 (fr) Agoniste de recepteur d'adenosine a2a et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
HK1217714A1 (zh) 治療組織炎症和癌變的鳥苷酸環化酶受體增效劑
MA26852A1 (fr) Agonistes selectifs du recepteur ep4 pour le traitement de l'osteoporose
MA27027A1 (fr) Inhibiteur de pde4 et agent anticholinergique en association pour le traitement de maladies obstructives des voies aeriennes
DE69937994D1 (de) Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
ZA988638B (en) Use of combinations comprising non-sedating antihistamines and alpha-adrenergic drugs for the topical treatment or rhinitis/conjunctivitis and cold cold-like and/or flu symptoms
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
EP1392292A4 (fr) Pyranoindazoles et leur utilisation dans le traitement du glaucome
IL211288A0 (en) Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
HK1061237A1 (en) 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain anxiety or gastrointestinal disorders
HUP0003852A3 (en) Use of highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
DE59903751D1 (de) 2',2'-difluornucleoside zur immunosuppressiven therapie und kombinationspräparate
EP1392658A4 (fr) Indazoles et indoles nouveaux fusionnes et leur utilisation dans le traitement de glaucomes
IL198759A (en) Use of 3gal receptor antagonists to prepare medications to treat depression and / or anxiety
DE60321730D1 (de) Agonisten des corticotropin-freisetzenden Faktor Rezeptors 2
EP0747055A3 (fr) Utilisation d'antagonistes du récepteur de tachykinine pour le traitement du rhume et de la rhinite allergique
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
FR2814367B1 (fr) Ligands du recepteur npff pour le traitement de la douleur et des hyperalgies
GB0507998D0 (en) Novel use of neuronal calcium sensor-1 (NCS-1) in therapy of CNS disorders and in the development of therapeutic agents
IL161669A (en) Chemokine receptor antagonists and methods of use thereof
AU2002212441A1 (en) Use of vanilloid 4 receptor and antagonists or agonists thereof for treating diseases associated with pain
NO20023841D0 (no) Anvendelse av glukokortikoidreseptorantagonister for forebygging og behandling av sykdommer av reproduksjonssystemethos menn
HU0005013D0 (en) Use of polidocanol for the treatment of the uterus and ovary of mammals